MolPharm xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] --
 QUICK SEARCH:   [advanced]


     


Molecular Pharmacology Fast Forward
First published on May 29, 2008; DOI: 10.1124/mol.108.048165


This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
mol.108.048165v1
74/3/736    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Google Scholar
Right arrow Articles by Adebiyi, A.
Right arrow Articles by Jaggar, J. H
PubMed
Right arrow PubMed Citation
Right arrow Articles by Adebiyi, A.
Right arrow Articles by Jaggar, J. H


Received for publication April 23, 2008.
Revised May 28, 2008.
Accepted for publication May 29, 2008.

Sulfonylurea Receptor-Dependent and -Independent Pathways Mediate Vasodilation Induced by KATP Channel Openers

Adebowale Adebiyi 1, Elizabeth M McNally 2, Jonathan H Jaggar 1*

1 University of Tennessee Health Science Center 2 University of Chicago, Chicago Illinois

* Address correspondence to: E-mail: jjaggar{at}physio1.utmem.edu

Abstract

ATP-sensitive K+ (KATP) channel openers are vasodilators that activate both plasma membrane and mitochondrial KATP channels. Here, we investigated the molecular mechanisms by which diazoxide and pinacidil induce vasodilation by studying diameter regulation of wild-type (SUR2+/+) and sulfonylurea receptor 2 deficient (SUR2-/-) mouse myogenic mesenteric arteries. Ryanodine (10 µM), a ryanodine-sensitive Ca2+ release (RyR) channel blocker, iberiotoxin (100 nM), a large-conductance Ca2+-activated K+ (KCa) channel blocker, 4-aminopyridine (4-AP, 1 mM), a Kv channel blocker, MnTMPyP (100 µM), an antioxidant, and a combination of ryanodine and 4-AP reduced diazoxide (100 µM)-induced dilation in pressurized (60 mmHg) SUR2+/+ arteries by 45-77 %. In contrast, these inhibitors did not alter pinacidil (5 µM)-induced dilation in SUR2+/+ arteries. RT-PCR indicated that SUR2B was the only SUR isoform expressed in SUR2+/+ mesenteric artery smooth muscle cells, whereas SURs were absent in SUR2-/- cells. In SUR2-/- arteries, pinacidil-induced vasodilation was ~10 % of that in SUR2+/+ arteries, whereas diazoxide-induced vasodilation was similar in SUR2+/+ and SUR2-/- arteries. Atpenin (1 µM), a selective electron transport chain complex II (ETCII) inhibitor, dilated arteries similarly to diazoxide and this effect was attenuated by MnTMPyP and ryanodine + 4-AP. Atpenin also attenuated diazoxide-, but not pinacidil-induced vasodilation. In summary, data indicate that pinacidil-induced vasodilation requires SUR2B, whereas diazoxide-induced vasodilation does not require SURs. Rather diazoxide-induced vasodilation involves ETCII inhibition, a smooth muscle cell reactive oxygen species elevation, and RyR, KCa, and Kv channel activation. These data indicate that KATP channel openers regulate arterial diameter via SUR-dependent and -independent pathways.


Key words: Ion channel regulation, Knockout





Home Help [Feedback] [For Subscribers] [Archive] [Search] --
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2008 by the American Society for Pharmacology and Experimental Therapeutics